MiNK Therapeutics, Inc. (INKT) News
Filter INKT News Items
INKT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest INKT News From Around the Web
Below are the latest news stories about MINK THERAPEUTICS INC that investors may wish to consider to help them evaluate INKT as an investment opportunity.
MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial ChallengesKey Financial and Operational Highlights from MiNK Therapeutics' Third Quarter |
MiNK Therapeutics Reports Third Quarter 2023 ResultsMiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress. MiNK plans for expansion in autoimmune and inflammatory diseases.Conference Call on Thursday, November 9, 2023, at 8:30 a.m. ET. NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a |
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioningAgenT-797 advancing in a randomized phase 2 trial in 2L gastric cancer NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allog |
MiNK Therapeutics Insider Ups Holding During YearLooking at MiNK Therapeutics, Inc.'s ( NASDAQ:INKT ) insider transactions over the last year, we can see that insiders... |
MiNK to Provide Third Quarter 2023 Financial Report and Corporate UpdateNEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on Thursday, Nov. 9, 2023. About MiNK Therapeutics M |
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agenT-797’s distinct mechanism of action in solid tumors. A poster will be presented |
Can MiNK Therapeutics (NASDAQ:INKT) Afford To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
MiNK Therapeutics to Participate in September Investor ConferencesNEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer and President, will participate in the following upcoming investor conferences: Baird 2023 Global Healthcare Conferenc |
MiNK Therapeutics Reports Second Quarter 2023 Results- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center - iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid Tumor Cancers and in Respiratory Distress - MiNK-215, a Novel FAP-CAR-iNKT Cell Therapy, Eliminated Tumors in NSCLC Models NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commer |
MiNK to Provide Second Quarter 2023 Financial Report and Corporate UpdateCompany announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release befo |